Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study-Reference-Cited by-同舟云学术

Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study

Published:2020-07-13 Issue:1 Volume:34 Page:77-84
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Mod Pathol

Author:

Bhargava Rohit^ORCID,Esposito Nicole N.,OʹConnor Siobhan M.,Li Zaibo^ORCID,Turner Bradley M.,Moisini Ioana,Ranade Aditi,Harris Ronald P.,Miller Dylan V.,Li Xiaoxian^ORCID,Moosavi Harrison,Clark Beth Z.,Brufsky Adam M.^ORCID,Dabbs David J.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Link

http://www.nature.com/articles/s41379-020-0620-2.pdf

Reference45 articles.

1. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:188–94.

2. Farrugia DJ, Landmann A, Zhu L, Diego EJ, Johnson RR, Bonaventura M, et al. Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors. Mod Pathol. 2017;30:1078–85.

3. Flanagan MB, Dabbs DJ, Brufsky AM, Beriwal S, Bhargava R. Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol. 2008;21:1255–61.

4. Klein ME, Dabbs DJ, Shuai Y, Brufsky AM, Jankowitz R, Puhalla SL, et al. Prediction of the oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Mod Pathol. 2013;26:658–64.

5. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17:6012–20.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond;Expert Review of Anticancer Therapy;2024-03-18

2. The Magee 3 Equation Predicts Favorable Pathologic Response to Neoadjuvant Endocrine Therapy in Breast Cancer Patients;Cancers;2024-01-13

3. PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to neoadjuvant chemotherapy in ER+/HER2- breast cancer;Frontiers in Oncology;2023-08-28

4. The budget impact of utilizing the Oncotype DX Breast Recurrence Score test from a US healthcare payer perspective;Journal of Medical Economics;2023-08-07

5. Clinicopathologic and genomic features of lobular like invasive mammary carcinoma: is it a distinct entity?;npj Breast Cancer;2023-07-13